Table 3.
Pharmacokinetic parameters of agomelatine in both plasma and brain.
| |
Rabbits plasma |
|
|
Rabbits brain |
|
|
|---|---|---|---|---|---|---|
| Parameters | Gel-3 | IV | Oral | Gel-3 | IV | Oral |
| Cmax (ng/mL) | 247.00 ± 64.40 | 423.00 ± 47.90 | 20.70 ± 3.19 | 148.33 ± 64.36 | 165.60 ± 37.70 | 61.20 ± 12.23 |
| Tmax (min) | 7.33 ± 4.62 | 2.00 ± 0.00 | 15.67 ± 14 | 2.00 ± 4.61 | 5.00 ± 0.00 | 5.00 ± 0.00 |
| AUC0– t (ng/mL min) | 6677.41 ± 1996.00 | 17,616.00 ± 2839.00 | 2828.10 ± 969.00 | 6570.23 ± 1995.50 | 12,499.60 ± 4166.50 | 1710.12 ± 378.24 |
| K (min−1) | 0.0041 ± 0.0004 | 0.0032 ± 0.0003 | 0.0079 ± 0.002 | |||
| t1/2 (min) | 378.93 ± 365.00 | 216.74 ± 23.80 | 91.98 ± 23.80 | |||
| MRT (min) | 225.28 ± 227.00 | 173.23 ± 5.59 | 151.64 ± 28.00 | 182.70 ± 227.07 | 163.19 ± 6.11 | 8206.90 ± 5505.04 |
| Absolute bioavailability | 37.89 | 16.12 | ||||
| Relative bioavailability | 234.98 | |||||
| Drug targeting efficiency (DTE) | 141.42 | |||||
| Direct transport percentage (DTP) | 29.29 |